Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin for adult patients suffering from metastatic or ...

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers ...

Libtayo works by attaching itself to a receptor called programmed cell death protein 1 (PD-1) on specific immune system cells called T cells. PD-1 can show up on these cells when cancer has ...

The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...

Results described in the paper more generally suggest that the molecular mechanism of programmed cell death has been conserved evolutionarily from worms to mammals. "Concerning evolutionary ...

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers ...

As a result, drugs that inhibit MCL-1 can inadvertently damage healthy tissues that rely on this protein for energy, especially in organs with high energy demand like the heart and liver, leading to ...

Mouse PD-1 is significantly weaker than human PD-1, which could have implications for using mice as models in PD-1 studies. Programmed cell death protein 1 (PD-1) has been a key target for cancer ...

A pioneering discovery at WEHI in 1988 of a protein that stopped programmed cell death sparked huge interest in the field, and has since led to a new drug to treat cancer.